Original language | English |
---|---|
Pages (from-to) | 1105-1118 |
Number of pages | 14 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 126 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2010 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Allergy and Clinical Immunology, Vol. 126, No. 6, 12.2010, p. 1105-1118.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Guidelines for the diagnosis and management of food allergy in the United States
T2 - Summary of the NIAID-sponsored expert panel report
AU - Boyce, Joshua A.
AU - Assa'ad, Amal
AU - Burks, A. Wesley
AU - Jones, Stacie M.
AU - Sampson, Hugh A.
AU - Wood, Robert A.
AU - Plaut, Marshall
AU - Cooper, Susan F.
AU - Fenton, Matthew J.
AU - Arshad, S. Hasan
AU - Bahna, Sami L.
AU - Beck, Lisa A.
AU - Byrd-Bredbenner, Carol
AU - Camargo, Carlos A.
AU - Eichenfield, Lawrence
AU - Furuta, Glenn T.
AU - Hanifin, Jon M.
AU - Jones, Carol
AU - Kraft, Monica
AU - Levy, Bruce D.
AU - Lieberman, Phil
AU - Luccioli, Stefano
AU - Mccall, Kathleen M.
AU - Schneider, Lynda C.
AU - Simon, Ronald A.
AU - Simons, F. Estelle R.
AU - Teach, Stephen J.
AU - Yawn, Barbara P.
AU - Schwaninger, Julie M.
N1 - Funding Information: M. Kraft has served as a consultant and/or speaker for Astra-Zeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sepracor. She has received funding/grant support from Genentech, GlaxoSmithKline, the National Institutes of Health and Novartis . Funding Information: S. H. Arshad has received funding/grant support from the National Institutes of Health and the National Institute of Health Research, UK . Funding Information: L. A. Beck has received funding/grant support from the American Academy of Allergy, Asthma, and Immunology, the National Eczema Association, and the National Institutes of Health . Funding Information: G. T. Furuta has served as a consultant and/or speaker to Ception Therapeutics and TAP. He has received funding/grant support from the American Gastrointestinal Association and the National Institutes of Health . Funding Information: R. A. Wood has served as a speaker/advisory board member for GlaxoSmithKline, Merck, and Dey. He has received funding/grant support from Genentech and the National Institutes of Health (National Institute of Allergy and Infectious Diseases). Funding Information: S. J. Teach has served as a speaker for AstraZeneca. He has received funding/grant support from the AstraZeneca Foundation, Aventis, the Child Health Center Board, the CNMC Research Advisory Council, the National Association of Chain Drug Stores Foundation, the National Institutes of Health (National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute), Novartis/Genentech, the Robert Woods Johnson Foundation, the US Centers for Disease Control and Prevention, the US Public Health Service, and the Washington, DC, Department of Health . Funding Information: L. C. Schneider has served as a consultant/clinical advisor for the Food Allergy Initiative. She has received funding/grant support from a variety of not-for-profit research foundations, as well as Novartis and the National Institutes of Health . Funding Information: A. W. Burks holds, or is listed as an inventor on, multiple US patents related to food allergy. He owns stock in Allertein and MastCell, Inc, and is a minority stockholder in Dannon Co Probiotics. He has served as a consultant for ActoGeniX NV, McNeil Nutritionals, Mead Johnson, and Novartis. He has served on the speaker's bureau for EpiPen/Dey, LP, and has served on the data monitoring committee for Genentech. He has served on an expert panel for Nutricia. Dr Burks has received funding/grant support from the Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson, and the National Institutes of Health . Funding Information: S. M. Jones has served as a speaker and grant reviewer and has served on the medical advisory committee for the Food Allergy and Anaphylaxis Network. She has received funding/grant support from Dyax Corp, the Food Allergy and Anaphylaxis Network, Mead Johnson, the National Peanut Board, and the National Institutes of Health . Funding Information: F. E. R. Simons holds a patent on “Fast-disintegrating epinephrine tablets for sublingual administration.” She is a past-president of the American Academy of Allergy, Asthma, and Immunology and of the Canadian Society of Allergy and Clinical Immunology. She is a member of the advisory boards of Dey, Intelliject, and ALK-Abello. She has received funding/grant support from AllerGen, the Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada, and the Canadian Institutes of Health Research . Funding Information: C. Byrd-Bredbenner owns stock in Johnson & Johnson. She has received funding/grant support from the US Department of Agriculture, the Canned Food Alliance, and the New Jersey Department of Health and Senior Services .
PY - 2010/12
Y1 - 2010/12
UR - http://www.scopus.com/inward/record.url?scp=78649828230&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2010.10.008
DO - 10.1016/j.jaci.2010.10.008
M3 - Article
C2 - 21134568
AN - SCOPUS:78649828230
SN - 0091-6749
VL - 126
SP - 1105
EP - 1118
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 6
ER -